Zealand Pharma A/S Revenue and Competitors
Estimated Revenue & Valuation
- Zealand Pharma A/S's estimated annual revenue is currently $301.9M per year.
- Zealand Pharma A/S's estimated revenue per employee is $768,219
- Zealand Pharma A/S's current valuation is $924M. (January 2022)
Employee Data
- Zealand Pharma A/S has 393 Employees.
- Zealand Pharma A/S grew their employee count by 22% last year.
Zealand Pharma A/S's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Commercial, VP | Reveal Email/Phone |
2 | VP, Business Development | Reveal Email/Phone |
3 | VP, Business Unit Head US Metabolic Diseases | Reveal Email/Phone |
4 | Head US Regulatory Affairs | Reveal Email/Phone |
5 | Controller | Reveal Email/Phone |
6 | Head Medical Writing | Reveal Email/Phone |
7 | SVP, Head People & Organization | Reveal Email/Phone |
8 | SVP | Reveal Email/Phone |
9 | Senior Director Finance | Reveal Email/Phone |
10 | EVP and Chief Operating Officer | Reveal Email/Phone |
Zealand Pharma A/S Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $10.1M | 65 | 5% | N/A | N/A |
#10 | $16.1M | 104 | 9% | N/A | N/A |
What Is Zealand Pharma A/S?
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand"?) is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand?s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand?s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.
keywords:N/A
N/A
Total Funding
393
Number of Employees
$301.9M
Revenue (est)
22%
Employee Growth %
$924M
Valuation
N/A
Accelerator
Zealand Pharma A/S News
Copenhagen, DK and Boston, MA, April 22, 2022 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based...
Copenhagen, DK and Boston, MA, US., April 20, 2022 Zealand Pharma A/S (Zealand) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), Copenhagen-based...
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, and development of peptide-based medicines.
Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide Company announcement - No. 70 / 2021 • Dapiglutide was assessed to be safe and well tolerated following 4 weeks of dosing in humans • Effects on several biomarkers sugges ...
Company announcement – No. 65/ 2021 Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity Preclinical data have shown potent anti-obesity effects of ZP8396 both as a monotherapy and in combination with a GLP1 analogue. Copenhagen, ...
Other Companies in Søborg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 411 | 14% | N/A |
#2 | $100.4M | 502 | 20% | N/A |
#3 | N/A | 760 | 24% | N/A |
#4 | $265.8M | 904 | 24% | N/A |
#5 | N/A | 1042 | 374% | N/A |